Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

Sirion Biotech GmbH. (4/27/15). "Press Release: Munich Based Sirion Biotech about to Open Office and Lab in Boston Massachusetts". Munich.

Region Region Boston, MA
  Country United States (USA)
Organisation Organisation Sirion Biotech GmbH
  Group Sirion Biotech (Group)
Products Product adeno-associated viral vector (AAV vector)
  Product 2 cancer vaccine

Viral Vector Technologies from Europe directly accessible in Boston

Another Germany company from within its highly innovative life science industry expands into the North American markets, SIRION Biotech in Munich. The company is a leader in the field of viral vectors.

Viral vectors (or virus vectors) are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery of new drug, food and cosmetic compounds. Of particular interest are viral vectors in vaccine development such as tumor treatment vaccines.

The company has gained market positions in German speaking countries, Japan, Korea and Israel. It grows fast at a rate of 40% p.a.. Interestingly, the US remains a challenge despite a common belief that similar cultural heritage and technical curiosity should allow for easy market access. Generating new customers is difficult, despite outstanding quality services. Setting up and managing complex project processes and keeping everyone updated, all these developments occur too far away for the Europe based contact. Despite internet and webinars, a sense of distance remains .

SIRION Biotech has over the last 2 years been recruiting and training binational professionals that are now on their way to Boston to establish a physical presence in the US. Boston has a large local market potential and time difference to Europe is only six hours: project inquiries come in in the afternoon, are being discussed with the Europe HQ first thing in the morning, project proposals and quotes are out with potential clients no later than 24 hours. Service levels realized in Europe can thus be offered to US clients as well.

About SIRION Biotech

SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 500 single projects with more than 150 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies both for research and clinical studies.

Contact SIRION Biotech USA:
Dr. Carl Christel
PO Box 3
Durham, NH 03824
Tel.: +1-(857) 284 1844

Record changed: 2019-01-13


Picture [iito] Plain Stupid Simple 650x80px

More documents for Sirion Biotech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top